Insight Molecular Diagnostics Inc. Files 8-K on Shareholder Vote

Ticker: IMDX · Form: 8-K · Filed: Jul 2, 2025 · CIK: 1642380

Sentiment: neutral

Topics: corporate-action, shareholder-vote, filing-update

TL;DR

Insight Molecular Diagnostics (formerly Oncocyte) filed an 8-K for a shareholder vote on June 27th.

AI Summary

Insight Molecular Diagnostics Inc. filed an 8-K on July 2, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 27, 2025. The company, formerly known as Oncocyte Corp, is incorporated in California and headquartered in Nashville, Tennessee.

Why It Matters

This filing indicates a significant corporate action involving shareholder approval, which could impact the company's strategic direction or governance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain immediate financial or operational risks.

Key Players & Entities

FAQ

What specific matters were submitted for a vote of security holders on June 27, 2025?

The filing does not specify the exact matters submitted for a vote, only that such a submission occurred.

What is the primary business of Insight Molecular Diagnostics Inc.?

Insight Molecular Diagnostics Inc. is in the business of IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES, as indicated by its SIC code.

When did Insight Molecular Diagnostics Inc. change its name from Oncocyte Corp?

The filing lists multiple previous name changes for Oncocyte Corp, with the most recent listed date of name change being September 20, 2021.

Where is Insight Molecular Diagnostics Inc. headquartered?

The company's principal executive offices are located at 2 International Plaza Dr., Suite 510, Nashville, Tennessee 37217.

What is the SEC file number for Insight Molecular Diagnostics Inc.?

The SEC file number for Insight Molecular Diagnostics Inc. is 001-37648.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding Insight Molecular Diagnostics Inc. (IMDX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing